Hikma Pharmaceuticals (Hikma), the multinational pharmaceutical company, has announced an exclusive licensing and distribution agreement with Sesen Bio , a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer. The licensing agreement provides Hikma with exclusive rights to commercialise and distribute Vicineum in the Mena region for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and other types of cancer. Vicineum, a locally ...